Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) insider Joseph Douglas Lyon sold 1,540 shares of the company’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $114.16, for a total transaction of $175,806.40. Following the completion of the sale, the insider owned 5,495 shares of the company’s stock, valued at $627,309.20. This represents a 21.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
Joseph Douglas Lyon also recently made the following trade(s):
- On Wednesday, May 27th, Joseph Douglas Lyon sold 5,000 shares of Corcept Therapeutics stock. The shares were sold at an average price of $65.00, for a total value of $325,000.00.
Corcept Therapeutics Price Performance
NASDAQ CORT opened at $110.69 on Thursday. Corcept Therapeutics Incorporated has a fifty-two week low of $28.66 and a fifty-two week high of $122.21. The stock’s 50-day moving average is $87.69 and its two-hundred day moving average is $58.49. The firm has a market cap of $11.97 billion, a P/E ratio of 263.55 and a beta of 0.45.
Institutional Trading of Corcept Therapeutics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CORT. Pathstone Holdings LLC increased its holdings in shares of Corcept Therapeutics by 0.8% during the 3rd quarter. Pathstone Holdings LLC now owns 18,013 shares of the biotechnology company’s stock worth $1,497,000 after acquiring an additional 144 shares during the last quarter. State of Wyoming lifted its holdings in Corcept Therapeutics by 29.5% during the 1st quarter. State of Wyoming now owns 816 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 186 shares during the last quarter. Gould Capital LLC boosted its position in Corcept Therapeutics by 50.0% during the third quarter. Gould Capital LLC now owns 600 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 200 shares during the period. Sequoia Financial Advisors LLC boosted its position in Corcept Therapeutics by 3.7% during the fourth quarter. Sequoia Financial Advisors LLC now owns 6,904 shares of the biotechnology company’s stock worth $240,000 after purchasing an additional 247 shares during the period. Finally, Evergreen Capital Management LLC increased its holdings in shares of Corcept Therapeutics by 3.0% in the fourth quarter. Evergreen Capital Management LLC now owns 8,609 shares of the biotechnology company’s stock valued at $300,000 after purchasing an additional 248 shares during the last quarter. Institutional investors and hedge funds own 93.61% of the company’s stock.
Analysts Set New Price Targets
Several brokerages have commented on CORT. Piper Sandler reiterated an “overweight” rating and set a $165.00 price target (up from $88.00) on shares of Corcept Therapeutics in a report on Thursday, July 30th. Truist Financial raised shares of Corcept Therapeutics to a “strong-buy” rating in a research report on Monday, June 15th. Canaccord Genuity Group boosted their price objective on shares of Corcept Therapeutics from $135.00 to $150.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. HC Wainwright upped their price objective on shares of Corcept Therapeutics from $95.00 to $165.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Finally, UBS Group set a $135.00 target price on shares of Corcept Therapeutics in a research note on Thursday, May 28th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $119.17.
Read Our Latest Stock Analysis on Corcept Therapeutics
About Corcept Therapeutics
Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.
The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.
Read More
- Five stocks we like better than Corcept Therapeutics
- SpaceX: Love the Company, But the Stock Is a Harder Call
- Ulta’s Growth Is Real, But So Are the Risks
- BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
- Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
